Treatment of Advanced Pancreatic Cancer
Authors:
- Michel DucreuxMDMichel Ducreux
- Valérie BoigeVBValérie Boige
- David MalkaDMDavid Malka
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 34, S25-S30
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancerCancer, 2006
- A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancerJournal of Clinical Oncology, 2005
- Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]Journal of Clinical Oncology, 2005
- Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2005
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996
- Chemotherapy prolongs survival in inoperable pancreatic carcinomaBritish Journal of Surgery, 1994